New Immune-Cell cocktail takes on tough gut cancers

NCT ID NCT06251973

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a five-drug combination for people with advanced esophageal, stomach, or gastroesophageal junction cancer that has worsened after initial treatment. The combination includes immune cells from healthy donors, two immunotherapy drugs, and two standard chemotherapy drugs. The main goal is to see how many patients' tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A combination of immune cells (agenT-797), two immunotherapy drugs (botensilimab and balstilimab), and two chemotherapy drugs (ramucirumab and paclitaxel)
What this could lead to: If successful, this could offer a new treatment option for people with advanced esophageal, stomach, or gastroesophageal junction cancer that has stopped responding to initial therapy.
What could go wrong: This is a small, early-phase (phase 2) trial with only 20 participants, so results may not apply broadly. The combination of multiple drugs also increases the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma esophageal cancer Esophageal Neoplasms gastric adenocarcinoma gastric cancer gastric carcinoma gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED UNRESECTABLE GASTRIC ADENOCARCINOMA METASTATIC ESOPHAGEAL ADENOCARCINOMA METASTATIC ESOPHAGEAL CANCER METASTATIC ESOPHAGEAL CARCINOMA METASTATIC GASTRIC ADENOCARCINOMA METASTATIC GASTRIC CANCER METASTATIC GASTRIC CARCINOMA METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA UNRESECTABLE ESOPHAGEAL CANCER UNRESECTABLE GASTRIC ADENOCARCINOMA UNRESECTABLE GASTRIC CARCINOMA UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.